Skip to Content

Advaxis Executive VP of Science and Operations Dr. John Rothman to Present at the 2009 Immunotherapeutics & Vaccine Summit (IMVACS)

Monday, August 17, 2009 at the Renaissance Providence Hotel, Providence, RI


Topic: “Live Bacterial Vaccines: The Use of Bioengineered Listeria Monocytogenes in the Clinic.”


NORTH BRUNSWICK, N.J.--(BUSINESS WIRE)--Aug 4, 2009 - Dr. John Rothman, executive vice president of science and operations at Advaxis, Inc. (OTCBB: ADXS), will present at the 2009 Immunotherapeutics & Vaccine Summit at the Renaissance Provident Hotel in Providence, RI on Monday, August 17, 2009.


Dr. Rothman presentation entitled “Live Bacterial Vaccines: The Use of Bioengineered Listeria Monocytogenes in the Clinic,” will review recent developments in Listeria as a vaccine, and update Advaxis' recent work on several constructs either in, or close to, clinical development.


About CHI


Cambridge Healthtech Institute (CHI) is the preeminent life science network for leading researchers and business experts from top pharmaceutical, biotech and academic organizations. CHI's portfolio of products includes Cambridge Healthtech Institute Conferences, Insight Pharma Reports, Cambridge Marketing Consultants, Barnett Educational Services, Cambridge Meeting Planners and Cambridge Healthtech's Media Group, which includes numerous e-newsletters as well as Bio-IT World magazine.


For more information, please visit the ImVac site:


About Advaxis, Inc.


Advaxis is a biotechnology company developing proprietary, attenuated, live Listeria Monocytogenes (Lm) vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer. Based in North Brunswick, NJ, the Company's drug platform is based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis' scientific advisory board.


For further information on the Company, please visit:


Forward-Looking Statements


Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company's current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.






Contact: Advaxis, Incorporated

Conrad Mir

Director, Business Development

732-545-1590 (Office)

732-545-1084 (FAX)



Posted: August 2009